Posted Jul 2nd 2009 11:30AM by Steven Halpern
Filed under: Major movement, International markets, Newsletters, NIKE, Inc'B' (NKE), DJIA, Stocks to Buy, Recession
"The conditions are in place for a 'Best Buy' opportunity," says Jim Stack, whose buy signal should receive special attention give the accuracy of his sells signals which side-stepped the bear market.
In addition, the money manager and editor of Investech Market Analyst is beginning to increase his equity positions, such as Nike (NYSE: NKE). He states, "With a portfolio of iconic brands, an identified growth strategy, recognized innovation, and sound financial footing, Nike fits the bill of being a great company."
"Very rarely do we have all these conditions in place – that's only occurred five times in the last 45 years. Historically, this means we should give the growing evidence of a new bull market every benefit of doubt.
Continue reading Step up to Nike (NKE): A 'great company'
Posted Jul 1st 2009 2:00PM by Steven Halpern
Filed under: International markets, China, Newsletters, Stocks to Buy
"China Unicom (NYSE: CHU) could be one of the best ways to play China's astounding economic growth," says Brandon Clay in Invest with an Edge. Here's the growth advisor's review.
"With the world's largest population as its market, the mobile phone industry in China is set to soar. This makes China Unicom a compelling play. The firm has 21% market share in China.
"China Unicom's vice president recently said the company is targeting subscriber growth of 20 million to 30 million within a year. To put that into context, Verizon Wireless, the largest mobile phone carrier in the U.S., had 72.1 million subscribers at the end of last year.
Continue reading China Unicom (CHU): Set to soar?
Posted Jun 30th 2009 3:40PM by Steven Halpern
Filed under: Newsletters, SanDisk Corp (SNDK), Stocks to Buy
"For two years chips stocks have unequivocally stunk; the industry has been mired in a host of problems, including massive overcapacity and shrinking demand," says Toby Smith, adding, "But that's changing."
In his ChangeWave Investing, he suggests, "One recommendation in this sector is SanDisk (NASDAQ: SNDK), the leader in flash memory -- one of the strongest segments in semis today."
"For the second quarter in a row the semiconductor sector is showing major signs of momentum that are so good that the industry ranked at the top of the nearly 20 industries we track each quarter.
"The bottom line is that these results clearly indicate that it is time to be invested in the semis, and the best way to do this is with two short-term plays.
Continue reading Toby Smith: In the chips with Sandisk
Posted Jun 29th 2009 4:30PM by Steven Halpern
Filed under: Microsoft (MSFT), Newsletters, Stocks to Buy
"Microsoft Corporation (NASDAQ: MSFT), already a holding on our buy list, was added to Goldman Sachs' Conviction Buy List," says Bill Martin. In BullMarket.com, he offers the reasoning for his continued buy rating.
"Analyst Sarah Friar at Goldman recently raised her price target on the name to $29 from $25 saying, 'We are adding Microsoft to our Conviction List as we think the combination of better revenue drivers, improved expense management, and sizable cash balances provides more opportunities for bottom-line beats.'
"'Windows 7, Windows Server 2008 R2, Bing, Xbox 360 and new Halo content, Office 2010, and the Azure Cloud provide renewed innovation beyond anything we have seen in multiple years,' Friar wrote.
Continue reading Microsoft (MSFT): Bet on Bing?
Posted Jun 26th 2009 1:30PM by Steven Halpern
Filed under: Newsletters, Urban Outfitters (URBN), Stocks to Buy, Recession
"Stocks have struggled lately after their huge recovery; still, I continue to see opportunities, and I especially like Urban Outfitters (NASDAQ: URBN)," says Mark Skousen in The Turnaround Alert.
"Urban Outfitters, the apparel retailer, after it beat Wall Street analysts' estimates. Two years ago, the stock was selling for $37 a share.
"But today, it's selling for nearly half that. During the deep recession, retailers have seen sales drop as consumers cut back on spending for clothing and other discretionary purchases. As a result, retail apparel stocks fell sharply.
Continue reading Urban Outfitters (URBN): Dressed for success?
Posted Jun 25th 2009 11:00AM by Steven Halpern
Filed under: Newsletters, Abbott Laboratories (ABT), Teva Pharm Indus ADR (TEVA), S and P 500, DJIA, Stocks to Buy
"Stocks are likely in a new downtrend," says Michael Ashbaugh. In Marketwatch's The Technical Indicator, he looks at the S&P's prospects and some drug stocks set to buck the trend.
"The S&P 500 has violated its major moving averages in the closely tracked 900 area. The recent downturn was convincingly bearish, placing the burden on market bulls to reassert the uptrend.
"After finding resistance in the 923 area, the S&P sold off sharply, edging back under its 200-day moving average, which currently holds at 900 and now marks resistance. This is bearish price action.
Continue reading Tech talk from MarketWatch
Posted Jun 24th 2009 12:00PM by Steven Halpern
Filed under: Newsletters, Stocks to Buy
Air Methods (NASDAQ: AIRM), which provides aeromedical emergency services and systems throughout the U.S., is a recent buy from technician Leo Fasciocco.
In his The Ticker Tape Digest, which focuses exclusively on stocks breaking out of basing patterns, he suggests, "AIRM is a turnaround stock that is acting strong now; with strong profits coming this year, we see good prospects for a breakout to the upside."
"AIRM, with annual revenues of $500 million, operates a fleet of aircraft, consisting of helicopters and airplanes. It serves hospitals in 26 states under contracts ranging from one to 10 years.
Continue reading Air Methods (AIRM): Emergency services by air
Posted Jun 24th 2009 10:00AM by Steven Halpern
Filed under: Newsletters, Stocks to Buy
"Emergency Medical Services Corp. (NYSE: EMS) is the leading provider of emergency medical services in the United States," notes growth stock expert David Fessler.
In The Oxford Club advisory, he explains, "Every three seconds, one of its staff member touches a patient in some facet of the patient care process: non-critical patient transport, 911-response services, emergency room staffing and other similar services."
"Hopefully you'll never require the services of an emergency medical crew -- like I did -- when I suffered a brain aneurism three years ago. I'll be forever grateful for their quick response and professional training. They probably saved my life.
Continue reading Emergency Medical (EMS): To the rescue
Posted Jun 23rd 2009 12:00PM by Steven Halpern
Filed under: Newsletters, Urban Outfitters (URBN), Stocks to Buy
"Stocks have struggled lately after their huge recovery; still, I continue to see opportunities in the market, and I especially like Urban Outfitters (NASDAQ: URBN)," says Mark Skousen in The Turnaround Alert.
"Urban Outfitters, the apparel retailer, after it beat Wall Street analysts' estimates. Two years ago, the stock was selling for $37 a share.
"But today, it's selling for nearly half that. During the deep recession, retailers have seen sales drop as consumers cut back on spending for clothing and other discretionary purchases. As a result, retail apparel stocks fell sharply.
Continue reading Urban Outfitters (URBN): Dressed for success?
Posted Jun 22nd 2009 1:40PM by Steven Halpern
Filed under: Newsletters, Stocks to Buy
"Biotech company Celgene Corp. (NASDAQ: CELG) is a prime example of a stock that plays both offense and defense," says Ian Wyatt.
In his Top Stock Insights, he explains, "The valuation is low and growth is attractive. With the pipeline of products in development, Celegene offers investors a huge upside potential."
"Celgene offers investors a steady product base, a variety of drug treatments in development and a cash pile ready to purchase existing technologies.
"Celgene engages in the discovery of therapies designed to treat cancer and immune-inflammatory related diseases. They have a number of products at the commercial stage.
Continue reading Celgene (CELG): Play offense and defense with biotech
Next Page »